Evolving expectations around early management of multiple sclerosis

Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis

(2011) R. A. Linker et al.   BRAIN

MRI criteria for MS in patients with clinically isolated syndromes

(2010) X. Montalban et al.   NEUROLOGY

Real-life impact of early interferonβ therapy in relapsing multiple sclerosis

(2009) M. Trojano et al.   ANNALS OF NEUROLOGY

Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta

(2009) Giancarlo Comi   CLINICAL THERAPEUTICS

Interferon-β therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism

(2009) David Azoulay et al.   JOURNAL OF NEUROIMMUNOLOGY

National MS registries

(2009) Peter Flachenecker et al.   JOURNAL OF NEUROLOGY

New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate

(2009) D Cadavid et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Deep gray matter atrophy in multiple sclerosis: A tensor based morphometry

(2009) Guozhi Tao et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

(2009) G Comi et al.   LANCET

Uncertain BENEFIT of early interferon beta-1b treatment

(2009) Sean J Pittock   LANCET NEUROLOGY

Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis

(2009) Bruce D Trapp et al.   LANCET NEUROLOGY

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

(2009) Ludwig Kappos et al.   LANCET NEUROLOGY

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

(2009) Paul O'Connor et al.   LANCET NEUROLOGY

Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study

(2009) E Portaccio et al.   Multiple Sclerosis Journal

Cognitive impairment predicts conversion to multiple sclerosis in clinically isolated syndromes

(2009) Valentina Zipoli et al.   Multiple Sclerosis Journal

Imaging outcomes for neuroprotection and repair in multiple sclerosis trials

(2009) Frederik Barkhof et al.   Nature Reviews Neurology

Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon β-1b

(2009) Carlo Lazzaro et al.   NEUROLOGICAL SCIENCES

Non-conventional MRI techniques for measuring neuroprotection, repair and plasticity in multiple sclerosis

(2008) Paul S Giacomini et al.   CURRENT OPINION IN NEUROLOGY

Distinct and Nonredundant In Vivo Functions of IFNAR on Myeloid Cells Limit Autoimmunity in the Central Nervous System

(2008) Marco Prinz et al.   IMMUNITY

IFN-β1b Induces Transient and Variable Gene Expression in Relapsing-Remitting Multiple Sclerosis Patients Independent of Neutralizing Antibodies or Changes in IFN Receptor RNA Expression

(2008) Anthony T. Reder et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome

(2008) Robert Zivadinov et al.   JOURNAL OF NEUROLOGY

Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile

(2008) C Lebrun et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Neurodegeneration in multiple sclerosis: The role of oxidative stress and excitotoxicity

(2008) R.E. Gonsette   JOURNAL OF THE NEUROLOGICAL SCIENCES

Cognitive impairment in multiple sclerosis

(2008) Nancy D Chiaravalloti et al.   LANCET NEUROLOGY

Novel therapeutic strategies for multiple sclerosis — a multifaceted adversary

(2008) Rocio S. Lopez-Diego et al.   NATURE REVIEWS DRUG DISCOVERY

Cognitive impairment and structural brain damage in benign multiple sclerosis

(2008) M. Rovaris et al.   NEUROLOGY

Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis

(2008) M. P. Amato et al.   NEUROLOGY

Metallothionein-III protects against 6-hydroxydopamine-induced oxidative stress by increasing expression of heme oxygenase-1 in a PI3K and ERK/Nrf2-dependent manner

(2008) Y HWANG et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Molecular mechanisms of the anti-inflammatory functions of interferons

(2007) Pavel Kovarik et al.   IMMUNOBIOLOGY

Cognitive impairment in different MS subtypes and clinically isolated syndromes

(2007) Constantin Potagas et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES